Related Experiment Videos
Drug interactions at the renal level. Implications for drug development
1Hoechst Marion Roussel, US Pharmacokinetics, Kansas City, Missouri, USA. peter.bonate@hmrag.com
Clinical Pharmacokinetics
|May 21, 1998
Summary
Clinically significant drug interactions involving the kidney are rare. This review covers renal drug elimination, interaction mechanisms, and models, concluding that widespread in vitro screening isn't necessary for drug development.
Area of Science:
- Pharmacology
- Nephrology
- Drug Development
Background:
- The kidney is crucial for drug elimination.
- Understanding renal drug interactions is vital for patient safety and effective drug development.
Purpose of the Study:
- Review renal elimination mechanisms.
- Identify potential renal drug interaction pathways.
- Evaluate models for studying renal drug interactions.
- Recommend strategies for drug development.
Main Methods:
- Literature review of renal elimination and drug interactions.
- Analysis of in vitro and in vivo animal models.
- Examination of human study designs for drug interaction mechanisms.
- Synthesis of findings to inform drug development.
Main Results:
- Clinically significant renal drug interactions causing toxicity are uncommon.
- Five mechanisms for renal drug interactions identified: displacement, tubular secretion/reabsorption competition, pH/flow changes, and metabolism inhibition.
- Competitive inhibition of tubular secretion is a well-known interaction.
- Significant interactions occur when renal clearance is high (>30%) and plasma concentrations exceed Michaelis-Menten constant, revealing nonlinear pharmacokinetics.
Conclusions:
- Widespread in vitro screening for renal drug interactions is not recommended during drug development.
- The potential for clinically significant renal drug interactions is limited under typical conditions.
- Factors like narrow therapeutic windows can increase interaction risk even with low renal clearance.